Innate Pharma (IPHA) Shares Outstanding (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Shares Outstanding data on file, last reported at $109.1 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding rose 21.78% year-over-year to $109.1 million; the trailing twelve-month figure through Dec 2025 stood at $109.1 million (up 21.78% YoY), and the FY2025 full-year result was $109.1 million, up 21.78% from the prior year.
• Shares Outstanding for Q4 2025 stood at $109.1 million, up from $89.6 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $109.1 million in Q4 2025 and bottomed at $81.2 million in Q4 2022.
• The 5-year median for Shares Outstanding is $89.6 million (2024), against an average of $91.5 million.
• The widest annual swing landed in 2022, when Shares Outstanding dropped 10.82%; it then grew 21.78% in 2025.
• A 5-year view of Shares Outstanding shows it stood at $91.0 million in 2021, then dropped by 10.82% to $81.2 million in 2022, then gained by 6.67% to $86.6 million in 2023, then advanced by 3.49% to $89.6 million in 2024, then grew by 21.78% to $109.1 million in 2025.
• The last three Shares Outstanding figures came in at $109.1 million (Q4 2025), $89.6 million (Q4 2024), and $86.6 million (Q4 2023), per Business Quant data.

Peer Comparison